Renaissance Capital LLC Cure Vac N.V. Transaction History

Renaissance Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 11, 2022	SELL	$13.18 - $19.41 $219,684 - $323,525	-16,668 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$14.73 - $35.25 $73,517 - $175,932	-4,991 Reduced 23.04%	16,668 $327,000
Q4 2021 Feb 01, 2022	SELL	$33.72 - $48.22 $127,967 - $182,994	-3,795 Reduced 14.91%	21,659 $743,000
Q3 2021 Feb 01, 2022	SELL	$49.26 - $74.5 $1.55 Million - $2.34 Million	-31,461 Reduced 55.28%	25,454 $1.39 Million
Q2 2021 Feb 01, 2022	SELL	$56.91 - $127.53 $3.82 Million - $8.55 Million	-67,068 Reduced 54.09%	56,915 $4.18 Million
Q1 2021 Feb 01, 2022	BUY	$79.79 - $126.29 $7.9 Million - $12.5 Million	98,967 Added 395.61%	123,983 $11.3 Million
Q4 2020 Feb 01, 2022	BUY	$46.76 - $136.27 $1.17 Million - $3.41 Million	25,016 New	25,016 $2.03 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Renaissance Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Capital LLC with notifications on news.